Vanda Pharmaceuticals Inc. (VNDA) Cash Flow Statement
Vanda Pharmaceuticals Inc. (VNDA) generated -$142.3M of operating cash flow over the twelve months to 2026-06-30, spent $674000 on capital expenditure and had free cash flow of -$143.0M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
VNDAVanda Pharmaceuticals Inc.Follow VNDA — free
—
Price chart with a free account
- Market cap
- 242.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 28 Oct, in 4 days
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -28.4 | -44.9 | -39.6 | -81.6 | 12.4 | -8.1 | -2.0 | 30.0 | 45.9 | 51.8 | 64.2 | 32.0 | 12.8 | -15.8 | -109.4 | -142.3 | |
| Capital expenditure | 0.3 | 2.0 | 0.2 | 0.8 | 2.5 | 1.4 | 1.7 | 0.4 | 1.0 | 1.8 | 0.6 | 0.7 | 0.4 | 0.5 | 1.0 | -0.7 | |
| Free cash flow | -28.7 | -46.9 | -39.8 | -82.3 | 9.9 | -9.5 | -3.6 | 29.6 | 44.9 | 50.0 | 63.7 | 31.3 | 12.4 | -16.2 | -110.4 | -143.0 | |
| Stock-based compensation | 5.5 | 5.0 | 5.4 | 5.9 | 8.0 | 8.5 | 10.5 | 11.7 | 13.5 | 13.4 | 15.4 | 16.3 | 14.0 | 12.4 | 9.5 | — |
USD millions · SEC XBRL
Vanda Pharmaceuticals Inc. — questions
- What is Vanda Pharmaceuticals Inc.'s operating cash flow?
- -$142.3M over the twelve months to 2026-06-30.
- How much does Vanda Pharmaceuticals Inc. spend on capital expenditure?
- $674000 over the twelve months to 2026-06-30.
- What is Vanda Pharmaceuticals Inc.'s free cash flow?
- -$143.0M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Vanda Pharmaceuticals Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.